ストックスクリーナーアプリを入手
486.84
2.33%
-11.59
前日終値:
$498.43
開ける：
$495.58
24時間の取引高:
984.49K
Relative Volume:
0.69
時価総額：
$123.52B
収益：
$12.34B
当期純損益:
$4.34B
株価収益率:
28.86
EPS:
16.8685
ネットキャッシュフロー:
$3.71B
1週間 パフォーマンス:
-7.80%
1か月 パフォーマンス:
+9.21%
6か月 パフォーマンス:
+4.95%
1年 パフォーマンス:
+1.64%
1日の値動き範囲:
$482.11
$500.77
1週間の範囲:
$482.11
$533.67
52週間の値動き範囲:
$362.50
$533.67
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
名前
Vertex Pharmaceuticals Inc
セクター
電話
(617) 341-6393
住所
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
486.67 | 126.50B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
666.17 | 69.50B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
911.78 | 56.92B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
323.61 | 43.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
192.62 | 40.34B | 742.00K | -1.37B | -1.07B | -7.0731 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | アップグレード | Maxim Group | Hold → Buy |
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-03-10 | 繰り返されました | Oppenheimer | Outperform |
| 2026-02-13 | アップグレード | Oppenheimer | Perform → Outperform |
| 2026-01-28 | 再開されました | Barclays | Overweight |
| 2026-01-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2026-01-06 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-25 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | 開始されました | Raymond James | Mkt Perform |
| 2025-08-06 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-12 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | アップグレード | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-19 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2024-12-09 | アップグレード | Jefferies | Hold → Buy |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-10-16 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-10 | 再開されました | Raymond James | Mkt Perform |
| 2024-08-05 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-06-27 | 開始されました | Redburn Atlantic | Buy |
| 2024-04-11 | アップグレード | Evercore ISI | In-line → Outperform |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2024-02-06 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2024-02-02 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | ダウングレード | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | 繰り返されました | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-05-04 | 再開されました | Piper Sandler | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Hold |
| 2023-01-17 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-06-01 | アップグレード | Maxim Group | Hold → Buy |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-05-06 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | 繰り返されました | JP Morgan | Overweight |
| 2022-01-27 | 繰り返されました | Morgan Stanley | Underweight |
| 2022-01-27 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-01-27 | 繰り返されました | Stifel | Hold |
| 2022-01-27 | 繰り返されました | Wolfe Research | Outperform |
| 2022-01-20 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | 開始されました | Wells Fargo | Overweight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-11-19 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | ダウングレード | Stifel | Buy → Hold |
| 2021-09-07 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | ダウングレード | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | 再開されました | Wolfe Research | Outperform |
| 2021-07-01 | 開始されました | Raymond James | Mkt Perform |
| 2021-06-11 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-12-30 | 開始されました | Daiwa Securities | Outperform |
| 2020-11-30 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | 開始されました | Bernstein | Outperform |
| 2020-10-28 | 開始されました | UBS | Buy |
| 2020-07-31 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-04-28 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-09-03 | アップグレード | Goldman | Neutral → Buy |
| 2019-08-01 | ダウングレード | Needham | Buy → Hold |
| 2019-05-23 | 再開されました | Citigroup | Buy |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-12 | 開始されました | Evercore ISI | In-line |
| 2019-03-26 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | ダウングレード | Maxim Group | Buy → Hold |
すべてを表示
Vertex Pharmaceuticals Inc (VRTX) 最新ニュース
Lobbying Update: $60,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Quiver Quantitative
CNBC ‘Final Trades’: Nvidia, Vertex Pharmaceuticals And More OnRoundhill Memory ETF (BATS:DRAM) - Benzinga
Vertex acquires Crinetics in $10bn endocrinology deal - European Pharmaceutical Review
Why Is Vertex Pharmaceuticals (NASDAQ:VRTX) Making Healthcare Headlines? - Kalkine Media
Vertex’s $10 Billion Crinetics Acquisition Lands Amid Record Stock High: Time to Buy? - NAI500
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex Pharmaceuticals Inc Stock (VRTX) Moved Down by 3.09% on Jul 8: Key Drivers Unveiled - TradingKey
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc.CRNX - Business Wire
Vertex Pharmaceutical agrees to buy Crinetics in US$10 billion deal - BNN Bloomberg
Vertex’s Crinetics Deal Balances Growth with Integration Risk - MarketBeat
PR News | Joele Frank Works Crinetics' $8.8B DealWed., Jul. 8, 2026 - O'Dwyer's PR
Vertex’s Crinetics Deal Balances Growth with Integration Risk - Investing.com
Stifel cuts Crinetics stock rating to hold on Vertex acquisition - Investing.com
Vertex (VRTX) Stock May Be 36% Undervalued Following Its $10b Deal - Yahoo Finance
American Vertex Pharmaceuticals acquires Crinetics for $10 billion - AKM.RU
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside - Trefis
Jefferies Adjusts Vertex Pharmaceuticals Price Target to $610 From $580 - Moomoo
Vertex Pharmaceuticals (VRTX) Buys Crinetics, Where Does Fair Value Sit Now? - Yahoo Finance
H.C. Wainwright reiterates Vertex stock Buy rating at $641 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Aligos Therapeutics (ALGS) and Vertex Pharmaceuticals (VRTX) - The Globe and Mail
Morgan Stanley Analyzes Vertex Pharmaceuticals' (VRTX.US) $10 Billion Acquisition of Crinetics: Completing Its Endocrinology Pipeline and Unlocking Growth Potential with Two Core Drugs - Moomoo
Vertex to acquire Crinetics in deal worth around $10.0bn - PMLiVE
Vertex carries M&A uptick into H2, IPOs and VC raises also grow, FDA on pace despite turmoil - BioSpace
Viking Therapeutics (VKTX) Draws Takeover Focus After Vertex's $10 Billion Crinetics Deal - Yahoo Finance
Vertex Is Paying a 102% Premium to Acquire Crinetics for $10 Billion. Here's Whether the Deal Is Worth It. - AOL.com
Vertex Pharmaceuticals Inc Stock Price Live, Charts & News - The Economic Times
Key facts: Vertex to Buy Crinetics for $10B at $85; RBC Raises Target; Q2 Results Aug 3 - TradingView
The $10B Integration Problem Vertex Hasn’t Solved Yet - The Clinical Trial Vanguard
VKTX Vs BCRX: Which Biotech Takeover Favorite Offers More Upside After Vertex’s $10B CRNX Deal? - Stocktwits
Narrow-Moat Vertex's Strong CF Cash Flows Support Expansion Into Endocrinology Via Crinetics - Morningstar
Vertex Is Buying Crinetics for $10 Billion. Here's What Investors Need to Know. - AOL.com
Why Crinetics Stock Doubled After Vertex’s $10 Billion Buyout - Yahoo Finance
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals in $10 Billion All-Cash Deal - Global Legal Chronicle
Investigation launched into Crinetics Pharma bo... - Pluang
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Vertex Pharma’s Growth Strategy Leads to Its Biggest-Ever M&A Deal - MedCity News
Healthcare Deals This Week: AstraZeneca, Novartis, Vertex - Law360
Vertex Pharmaceuticals EVP sells $787,485 in company stock - Investing.com
Vertex Pharmaceuticals EVP sells $787,485 in company stock By Investing.com - Investing.com Nigeria
Form 4 Vertex Pharmaceuticals Inc For: 7 July By Investing.com - Investing.com Nigeria
Vertex (VRTX) Is Buying Crinetics For $10 Billion And Entering Endocrinology - Yahoo Finance
Vertex to Announce Second Quarter 2026 Financial Results on August 3rd - Business Wire
Why Crinetics (NASDAQ:CRNX) Nearly Doubled Today After Vertex’s US$10 Billion Takeover - Stocks Down Under
The Changing Reality of Pharmaceutical Commercialization | PharmExec - Pharmaceutical Executive
Vertex Pays $10 Billion to Enter Rare Endocrine Disease - TradingView
Vertex's $10B Crinetics deal marks its clearest step yet toward biopharma's top ranks - Endpoints News
This Biotech Stock Is Soaring 99% After Vertex Agrees to Takeover Deal - Barron's
Recon: Vertex buys Crinetics for $10B; EMA fast tracks Revolution’s metastatic pancreatic cancer drug - RAPS
Vertex to Acquire Crinetics Pharmaceuticals for $10 Billion - Pharmaceutical Executive
Vertex Pharmaceuticals' Acquisition of Crinetics Adds Rare-Disease Drugs, UBS Says - Moomoo
Vertex Pharmaceuticals Inc (VRTX) 財務データ
収益
当期純利益
現金流量
EPS
0.43%
0.38%
大文字化:
|
ボリューム (24 時間):